Sign in
Taking people in United StatesPhase 1

Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
15 people, planned
Started
26 Oct 2023
Expected to end
26 Nov 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Hyperpolarized 13C-Pyruvate
Record updated
11 May 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • History of acute head injury with or suspected non-penetrating acute TBI
  • Suitable to undergo contrast-enhanced MRI
  • Negative serum pregnancy test

Who cannot take part

  • Inability to receive IV MRI contrast agents secondary to severe reaction or renal insufficiency
  • Inability to undergo MRI scan
  • Positive pregnancy test

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial is currently available in United States.

  • University of Maryland, BaltimoreBaltimore, United StatesContact: Rosy Linda Njonkou TchoquessiTaking people

About the trial

What the trial wants to find out

The purpose of this study is to examine the safety and feasibility of using hyperpolarized metabolic MRI to study early brain metabolism changes in subjects presenting with head injury and suspected non-penetrating traumatic brain injury (TBI). This study will also compare HP pyruvate MRI-derived metrics in TBI patients with healthy subjects as well as Subarachnoid hemorrhage (SAH) patients to better understand if metabolic Magnetic resonance imaging scan (MRI) can improve our ability to diagnose a TBI.

Read full original descriptionShow less

The FDA is allowing the use of hyperpolarized [1-13C] pyruvate (HP 13C-pyruvate) in this study.

Up to 15 patients (5 with TBI, 5 with SAH, and 5 healthy volunteers) may take part in this study at the University of Maryland, Baltimore (UMB).

The 3 groups in the trial

  • Metabolic MRI in traumatic brain injury patientsTreatment being tested

    Perform metabolic magnetic resonance imaging on patients who have traumatic brain injury to understand early brain metabolism changes in this population

    Treatment: Hyperpolarized 13C-Pyruvate

  • Metabolic MRI in subarachnoid hemorrhage patientsTreatment being tested

    Perform metabolic magnetic resonance imaging on patients who have subarachnoid hemorrhage to understand early brain metabolism changes in this population

    Treatment: Hyperpolarized 13C-Pyruvate

  • Metabolic MRI in healthy volunteersTreatment being tested

    Perform metabolic magnetic resonance imaging on healthy volunteers to understand early brain metabolism changes in this population

    Treatment: Hyperpolarized 13C-Pyruvate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Utility of Hyperpolarized 13C-Pyruvate Metabolic Magnetic Resonance Imaging in the Diagnosis of Early Cerebral Metabolic Crisis After Traumatic Brain Injury
Criteria questions
Built from NCT06103201, who can take part
Record updated
11 May 2025